Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Breeze Holdings Acquisition (BREZU)
Upcoming IPO
AMMO (POWW)
Vision Marine Technologies (VMAR)
Spring Valley Acquisition (SVSVU)
Genesis Park Acquisition (GNPK.U)
Ozon Holdings Plc (OZON)
Tiga Acquisition (TINVU)
Spartan Acquisition Corp. II (SPRQ.U)
Priced IPO
Sotera Health Company (SHC)
Maravai LifeSciences Holdings, Inc. (MRVI)
Telos Corporation (TLS)
NeoGames S.A (NGMS)
Olema Pharmaceuticals, Inc. (OLMA)
Yatsen Holding Limited (YSG)
Lufax Holding Ltd (LU)
Atea Pharmaceuticals, Inc. (AVIR)
SQZ Biotechnologies Company (SQZ)
Allegro MicroSystems, Inc. (ALGM)
Galecto, Inc. (GLTO)
Leslie's Inc (LESL)
Gatos Silver, Inc. (GATO)
Biodesix, Inc. (BDSX)
MediaAlpha, Inc. (MAX)
Root, Inc. (ROOT)
Absolute Software (ABST)
EQT Corporation (EQT)
Foghorn Therapeutics Inc. (FHTX)
McAfee Corp. (MCFE)
More companies

SQZ Biotechnologies Company (SQZ)

Sector - Healthcare

Price chart

Company News

IPO Profile

About company

They are a clinical-stage biotechnology company developing transformative cell therapies for patients with cancer, infectious diseases and other serious conditions. They use their proprietary technology, Cell Squeeze, to physically squeeze cells through a microfluidic chip, temporarily opening the cell membrane and enabling biologic material of interest, or cargo, to diffuse into the cell. This technology allows them to create a broad pipeline of product candidates for different diseases. They believe their Cell Squeeze technology has the potential to create well-tolerated cell therapies that can provide therapeutic benefit for patients. Their potential benefits include accelerated timelines with production time under 24 hours, compared to four to six weeks for other existing cell therapies, improved patient experience by eliminating the need for pre-conditioning or lengthy hospital stays, and broadened therapeutic impact. Their goal is to use the SQZ approach to establish a new paradigm for cell therapies. They are using Cell Squeeze to create multiple cell therapy platforms focused on directing specific immune responses. Their most advanced platform in development, SQZ Antigen Presenting Cells (SQZ APC), is currently in a Phase 1 trial in HPV+ tumors. Their additional platforms currently in development are SQZ Activating Antigen Carriers (SQZ AAC) and SQZ Tolerizing Antigen Carriers (SQZ TAC). They are leveraging each of these platforms to create differentiated product candidates that have applicability across multiple disease areas.
Industry
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)
CEO CFO
Armon Sharei Teri Loxam
Employees Founded
101 2013

Contacts

Address: 200 Arsenal Yards Blvd, Suite 210 Watertown, MA 02472

Telephone: (617) 758-8672

Web page: http://www.SQZbiotech.com

IPO information

Expected Date 10/30/2020
Status Priced
Exchange NYSE
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Financial Data (last reporting year)

Market Cap (MM) $383.6
Revenues (MM) $22.82
Net Income (Loss) (MM) $-38.71

Voting

What do you think will happen with the SQZ share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
Shares Initial (MM) 4.4
Shares Revised (MM) 4.4
Expected offer amount (MM) $74.8
Realized offer amount(MM) $70.4
Underwriters
BofA Securities/ Stifel
CO-Managers
BTIG

Sector: Healthcare

Tweets about $SQZ

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats